24-Apr-2026 Virtual AGM online guide Virtual AGM online guide

24-Apr-2026 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

24-Apr-2026 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

24-Apr-2026 Appendix 4G Appendix 4G

24-Apr-2026 2025 Annual Report to shareholders 2025 Annual Report to shareholders

24-Apr-2026 2025 Annual Report to shareholders 2025 Annual Report to shareholders

24-Apr-2026 2025 Annual Report to shareholders 2025 Annual Report to shareholders

21-Apr-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

20-Apr-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

17-Apr-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

10-Apr-2026 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

8-Apr-2026 Jon Pilcher on Ausbiz: Neuren powers ahead with new Rett Syndrome treatment in US Jon Pilcher on Ausbiz: Neuren powers ahead with new Rett Syndrome treatment in US

26-Mar-2026 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

24-Mar-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

15-Mar-2026 Corporate Governance Corporate Governance

13-Mar-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

11-Mar-2026 Privacy Policy Privacy Policy

10-Mar-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

6-Mar-2026 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

4-Mar-2026 Analyst Coverage Analyst Coverage

4-Mar-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

4-Mar-2026 Jon Pilcher on Ausbiz: Acadia fuels Neuren's growth despite "old news" EU hurdle Jon Pilcher on Ausbiz: Acadia fuels Neuren's growth despite "old news" EU hurdle

27-Feb-2026 Investor presentation, 27 February 2026 Investor presentation, 27 February 2026

27-Feb-2026 Investor presentation, 27 February 2026 Investor presentation, 27 February 2026

27-Feb-2026 Investor presentation, 27 February 2026 Investor presentation, 27 February 2026

27-Feb-2026 Investor presentation, 27 February 2026 Investor presentation, 27 February 2026

13-Feb-2026 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

12-Feb-2026 Investor Webinar 12 February 2026 Investor Webinar 12 February 2026

11-Feb-2026 Notification of buy-back - NEU Notification of buy-back - NEU

11-Feb-2026 Notification of Neuren investor webinar on 12 February 2026 Notification of Neuren investor webinar on 12 February 2026

5-Feb-2026 Priority Review Voucher program reauthorized by US Congress Priority Review Voucher program reauthorized by US Congress

5-Feb-2026 Priority Review Voucher program reauthorized by US Congress Priority Review Voucher program reauthorized by US Congress

14-Jan-2026 Jon Pilcher on Ausbiz: Neuren boosted by favourable sales forecast Jon Pilcher on Ausbiz: Neuren boosted by favourable sales forecast

7-Jan-2026 NNZ-2591 PMS Phase 2 trial published in Neurology Genetics NNZ-2591 PMS Phase 2 trial published in Neurology Genetics

7-Jan-2026 NNZ-2591 PMS Phase 2 trial published in Neurology Genetics NNZ-2591 PMS Phase 2 trial published in Neurology Genetics

22-Dec-2025 Health Canada approves Clinical Trial Application for Koala Health Canada approves Clinical Trial Application for Koala

22-Dec-2025 Health Canada approves Clinical Trial Application for Koala Health Canada approves Clinical Trial Application for Koala

9-Dec-2025 One-month administrative delay to FDA meeting for HIE One-month administrative delay to FDA meeting for HIE

9-Dec-2025 One-month administrative delay to FDA meeting for HIE One-month administrative delay to FDA meeting for HIE

29-Nov-2025 Marcus Today On the Couch with Jon Pilcher Neuren Pharma CEO - November 2025 Marcus Today On the Couch with Jon Pilcher Neuren Pharma CEO - November 2025

24-Nov-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

24-Nov-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

10-Nov-2025 Investor Presentation, 10 November 2025 Investor Presentation, 10 November 2025

10-Nov-2025 Investor Presentation, 10 November 2025 Investor Presentation, 10 November 2025

10-Nov-2025 Investor Presentation, 10 November 2025 Investor Presentation, 10 November 2025

7-Nov-2025 Jon Pilcher on Ausbiz: Neuren eyes global growth as DAYBUE sales impress Jon Pilcher on Ausbiz: Neuren eyes global growth as DAYBUE sales impress

30-Oct-2025 Contact Us Contact Us

30-Oct-2025 Corporate Directory Corporate Directory

22-Oct-2025 Inside NEU: The ASX pharma star with a long runway for growth Inside NEU: The ASX pharma star with a long runway for growth

22-Oct-2025 Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of NNZ-2591 in Children and Adolescents With Pitt Hopkins Syndrome Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of NNZ-2591 in Children and Adolescents With Pitt Hopkins Syndrome

22-Oct-2025 Development of Clinician- and Caregiver-Reported Outcome Measures for Evaluating Pitt Hopkins Syndrome Development of Clinician- and Caregiver-Reported Outcome Measures for Evaluating Pitt Hopkins Syndrome

22-Oct-2025 NNZ-2591 for the Treatment of Angelman Syndrome: Results From a Phase 2 Open-Label Study NNZ-2591 for the Treatment of Angelman Syndrome: Results From a Phase 2 Open-Label Study

22-Oct-2025 Refining Clinician- and Caregiver-Reported Outcome Measures for Evaluating Phelan-McDermid Syndrome Refining Clinician- and Caregiver-Reported Outcome Measures for Evaluating Phelan-McDermid Syndrome

20-Oct-2025 Jon Pilcher on Ausbiz Jon Pilcher on Ausbiz

20-Oct-2025 Pipeline Pipeline

20-Oct-2025 Trofinetide in Rett Syndrome Trofinetide in Rett Syndrome

20-Oct-2025 DAYBUE® (trofinetide) DAYBUE® (trofinetide)

17-Oct-2025 Change of registered office in Australia Change of registered office in Australia

17-Oct-2025 Change of registered office in Australia Change of registered office in Australia

3-Oct-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

22-Sep-2025 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

19-Sep-2025 Biotech Showcase 2025 presentation Biotech Showcase 2025 presentation

9-Sep-2025 Neuren partners with Hope for HIE to support NNZ-2591 Neuren partners with Hope for HIE to support NNZ-2591

9-Sep-2025 Neuren partners with Hope for HIE to support NNZ-2591 Neuren partners with Hope for HIE to support NNZ-2591

8-Sep-2025 Change of Director's Interest Notice Change of Director's Interest Notice

28-Aug-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

27-Aug-2025 Investor Presentation, 27 August 2025 Investor Presentation, 27 August 2025

27-Aug-2025 Investor Presentation, 27 August 2025 Investor Presentation, 27 August 2025

27-Aug-2025 Investor Presentation, 27 August 2025 Investor Presentation, 27 August 2025

27-Aug-2025 Investor Presentation, 27 August 2025 Investor Presentation, 27 August 2025

27-Aug-2025 H1 2025 profit after tax A$15m, up from A$8m in H1 2024 H1 2025 profit after tax A$15m, up from A$8m in H1 2024

27-Aug-2025 H1 2025 profit after tax A$15m, up from A$8m in H1 2024 H1 2025 profit after tax A$15m, up from A$8m in H1 2024

13-Aug-2025 Science Behind Neuren's Products Science Behind Neuren's Products

13-Aug-2025 Corporate Directory Corporate Directory

12-Aug-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

7-Aug-2025 Compassionate Use Statement Compassionate Use Statement

22-Jul-2025 Change of Director's Interest Notice - J Pilcher Change of Director's Interest Notice - J Pilcher

22-Jul-2025 Change of Director's Interest Notice - J Pilcher Change of Director's Interest Notice - J Pilcher

22-Jul-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

22-Jul-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

9-Jul-2025 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

30-Jun-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

25-Jun-2025 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

16-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

16-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

13-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

12-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

11-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

10-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

6-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

5-Jun-2025 Neuren Pharmaceuticals: Under the Microscope Neuren Pharmaceuticals: Under the Microscope

5-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

4-Jun-2025 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

4-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

3-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

2-Jun-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

30-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

29-May-2025 Many Apparent False Negatives in Detection of Mutations in Gene Associated With Autism Spectrum Disorders Many Apparent False Negatives in Detection of Mutations in Gene Associated With Autism Spectrum Disorders

29-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

28-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

27-May-2025 Results of Meeting Results of Meeting

27-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

26-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

23-May-2025 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

23-May-2025 Approval of long-term equity incentive Approval of long-term equity incentive

23-May-2025 Approval of long-term equity incentive Approval of long-term equity incentive

23-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

22-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

21-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

20-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

19-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

16-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

15-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

14-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

13-May-2025 NEU receives FDA minutes and re-confirms Phase 3 endpoints NEU receives FDA minutes and re-confirms Phase 3 endpoints

13-May-2025 NEU receives FDA minutes and re-confirms Phase 3 endpoints NEU receives FDA minutes and re-confirms Phase 3 endpoints

13-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

12-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

9-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

8-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

7-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

6-May-2025 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

6-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

5-May-2025 Becoming a substantial holder Becoming a substantial holder

5-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

2-May-2025 Neuren appoints Daryl DeKarske to executive team Neuren appoints Daryl DeKarske to executive team

2-May-2025 Neuren appoints Daryl DeKarske to executive team Neuren appoints Daryl DeKarske to executive team

2-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

1-May-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

30-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

29-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

28-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

24-Apr-2025 Virtual AGM online guide Virtual AGM online guide

24-Apr-2025 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

24-Apr-2025 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

24-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

23-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

22-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

17-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

16-Apr-2025 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

16-Apr-2025 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

7-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

4-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

3-Apr-2025 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

3-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

3-Apr-2025 Appendix 4G Appendix 4G

3-Apr-2025 2024 Annual Report to shareholders 2024 Annual Report to shareholders

3-Apr-2025 2024 Annual Report to shareholders 2024 Annual Report to shareholders

3-Apr-2025 2024 Annual Report to shareholders 2024 Annual Report to shareholders

2-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

1-Apr-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

31-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

28-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

27-Mar-2025 Hypoxic-ischemic encephalopathy Hypoxic-ischemic encephalopathy

27-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

26-Mar-2025 NNZ-2591, a Synthetic IGF-1 Metabolite Analog: Phase 2 Clinical Trial Results for Children and Adolescents With Pitt Hopkins Syndrome NNZ-2591, a Synthetic IGF-1 Metabolite Analog: Phase 2 Clinical Trial Results for Children and Adolescents With Pitt Hopkins Syndrome

26-Mar-2025 Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan‑McDermid Syndrome in Children and Adolescents Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan‑McDermid Syndrome in Children and Adolescents

26-Mar-2025 The Evolving Genetic Landscape of Phelan-McDermid Syndrome and Implications for Diagnostics The Evolving Genetic Landscape of Phelan-McDermid Syndrome and Implications for Diagnostics

26-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

25-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

24-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

21-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

20-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

19-Mar-2025 belldirect interview belldirect interview

19-Mar-2025 belldirect interview belldirect interview

19-Mar-2025 Sharecafe and Finance News Network presentation Sharecafe and Finance News Network presentation

19-Mar-2025 Sharecafe and Finance News Network presentation Sharecafe and Finance News Network presentation

19-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

18-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

17-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

14-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

13-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

12-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

12-Mar-2025 Becoming a substantial holder Becoming a substantial holder

12-Mar-2025 Becoming a substantial holder Becoming a substantial holder

11-Mar-2025 Application for quotation of securities - NEU Application for quotation of securities - NEU

11-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

10-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

7-Mar-2025 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

7-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

6-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

6-Mar-2025 Ceasing to be a substantial holder Ceasing to be a substantial holder

5-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

4-Mar-2025 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

3-Mar-2025 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

28-Feb-2025 2024 Full Year Results Webinar 2024 Full Year Results Webinar

28-Feb-2025 2024 Full Year Results Webinar 2024 Full Year Results Webinar

28-Feb-2025 2024 Full Year Results webinar 2024 Full Year Results webinar

27-Feb-2025 Neuren 2024 results investor webinar on 28 February 2025 Neuren 2024 results investor webinar on 28 February 2025

25-Feb-2025 Becoming a substantial holder Becoming a substantial holder

25-Feb-2025 Becoming a substantial holder Becoming a substantial holder

7-Feb-2025 Type C Meeting granted by FDA for Phelan-McDermid syndrome Type C Meeting granted by FDA for Phelan-McDermid syndrome

7-Feb-2025 Type C Meeting granted by FDA for Phelan-McDermid syndrome Type C Meeting granted by FDA for Phelan-McDermid syndrome

6-Feb-2025 Neuren to present at autism research meeting Neuren to present at autism research meeting

6-Feb-2025 Neuren to present at autism research meeting Neuren to present at autism research meeting

28-Jan-2025 Share Registry Share Registry

22-Jan-2025 NEU Presentations at ACMG Annual Clinical Genetics Meeting NEU Presentations at ACMG Annual Clinical Genetics Meeting

22-Jan-2025 NEU Presentations at ACMG Annual Clinical Genetics Meeting NEU Presentations at ACMG Annual Clinical Genetics Meeting

20-Jan-2025 43rd J.P. Morgan Healthcare Conference Presentation Webcast 43rd J.P. Morgan Healthcare Conference Presentation Webcast

20-Jan-2025 43rd J.P. Morgan Healthcare Conference Presentation Webcast 43rd J.P. Morgan Healthcare Conference Presentation Webcast

20-Jan-2025 J.P. Morgan Healthcare Conference recap J.P. Morgan Healthcare Conference recap

20-Jan-2025 J.P. Morgan Healthcare Conference recap J.P. Morgan Healthcare Conference recap

16-Jan-2025 Neuren JP Morgan Healthcare Conference 2025 presentation Neuren JP Morgan Healthcare Conference 2025 presentation

16-Jan-2025 Neuren JP Morgan Healthcare Conference 2025 presentation Neuren JP Morgan Healthcare Conference 2025 presentation

16-Jan-2025 Neuren JP Morgan Healthcare Conference 2025 presentation Neuren JP Morgan Healthcare Conference 2025 presentation

18-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

18-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

17-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

17-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

16-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

16-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

13-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

13-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

12-Dec-2024 Priority Review Voucher sale complete Priority Review Voucher sale complete

12-Dec-2024 Priority Review Voucher sale complete Priority Review Voucher sale complete

12-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

12-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

11-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

11-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

10-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

10-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

9-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

9-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

6-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

6-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

5-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

5-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

4-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

4-Dec-2024 Update - Notification of buy-back - NEU Update - Notification of buy-back - NEU

15-Nov-2024 Investor presentation, 15 November 2024 Investor presentation, 15 November 2024

15-Nov-2024 Investor presentation, 15 November 2024 Investor presentation, 15 November 2024

14-Nov-2024 Notification of buy-back - NEU Notification of buy-back - NEU

14-Nov-2024 Notification of buy-back - NEU Notification of buy-back - NEU

13-Nov-2024 Marcus Today On the Couch podcast with Jon Pilcher Marcus Today On the Couch podcast with Jon Pilcher

13-Nov-2024 Marcus Today On the Couch podcast with Jon Pilcher Marcus Today On the Couch podcast with Jon Pilcher

11-Nov-2024 Improving Outcome Measures for Trials in Phelan-McDermid Syndrome (PMS): Development of PMS-Specific Clinician and Caregiver Impression-of-Change Measures Improving Outcome Measures for Trials in Phelan-McDermid Syndrome (PMS): Development of PMS-Specific Clinician and Caregiver Impression-of-Change Measures

11-Nov-2024 NNZ-2591, A Novel IGF-1–Related Treatment for Neurodevelopmental Disorders, Demonstrates Efficacy for Children and Adolescents With Phelan-McDermid Syndrome NNZ-2591, A Novel IGF-1–Related Treatment for Neurodevelopmental Disorders, Demonstrates Efficacy for Children and Adolescents With Phelan-McDermid Syndrome

6-Nov-2024 NNZ-2591 in Phelan-McDermid Syndrome NNZ-2591 in Phelan-McDermid Syndrome

1-Nov-2024 Updated Share Trading Policy Updated Share Trading Policy

1-Nov-2024 Updated Share Trading Policy Updated Share Trading Policy

28-Oct-2024 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

28-Oct-2024 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

25-Oct-2024 ASX CEO Connect ASX CEO Connect

25-Oct-2024 ASX CEO Connect ASX CEO Connect

16-Oct-2024 ShareCafe Small Cap Hidden Gems Presentation ShareCafe Small Cap Hidden Gems Presentation

16-Oct-2024 ShareCafe Small Cap Hidden Gems Presentation ShareCafe Small Cap Hidden Gems Presentation

16-Oct-2024 ShareCafe Small Cap Hidden Gems Presentation ShareCafe Small Cap Hidden Gems Presentation

14-Oct-2024 Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan-McDermid Syndrome in Children and Adolescents Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan-McDermid Syndrome in Children and Adolescents

7-Oct-2024 Investor webinar: Neuren continues PMS Phase 3 preparations following positive FDA meeting Investor webinar: Neuren continues PMS Phase 3 preparations following positive FDA meeting

7-Oct-2024 Investor webinar: Neuren continues PMS Phase 3 preparations following positive FDA meeting Investor webinar: Neuren continues PMS Phase 3 preparations following positive FDA meeting

27-Aug-2024 H1 2024 financial results H1 2024 financial results

27-Aug-2024 H1 2024 financial results H1 2024 financial results

19-Aug-2024 Investor roadshow presentation, 19 August 2024 Investor roadshow presentation, 19 August 2024

19-Aug-2024 Investor roadshow presentation, 19 August 2024 Investor roadshow presentation, 19 August 2024

19-Aug-2024 Investor roadshow presentation, 19 August 2024 Investor roadshow presentation, 19 August 2024

16-Aug-2024 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

16-Aug-2024 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

13-Aug-2024 Company Values Company Values

12-Aug-2024 NNZ-2591 in Angleman Syndrome NNZ-2591 in Angleman Syndrome

9-Aug-2024 Investor webinar: NNZ-2591 Angelman syndrome Phase 2 trial top-line results Investor webinar: NNZ-2591 Angelman syndrome Phase 2 trial top-line results

9-Aug-2024 Investor webinar: NNZ-2591 Angelman syndrome Phase 2 trial top-line results Investor webinar: NNZ-2591 Angelman syndrome Phase 2 trial top-line results

9-Aug-2024 NNZ-2591 Angelman top-line results presentation NNZ-2591 Angelman top-line results presentation

9-Aug-2024 NNZ-2591 Angelman top-line results presentation NNZ-2591 Angelman top-line results presentation

9-Aug-2024 NNZ-2591 Angelman top-line results presentation NNZ-2591 Angelman top-line results presentation

25-Jul-2024 Neuren to participate in upcoming US investor conferences Neuren to participate in upcoming US investor conferences

25-Jul-2024 Neuren to participate in upcoming US investor conferences Neuren to participate in upcoming US investor conferences

22-Jul-2024 Contact Us Contact Us

19-Jul-2024 Ceasing to be a substantial holder Ceasing to be a substantial holder

19-Jul-2024 Ceasing to be a substantial holder Ceasing to be a substantial holder

3-Jul-2024 NNZ-2591 in Prader-Willi syndrome NNZ-2591 in Prader-Willi syndrome

3-Jul-2024 NNZ-2591 in Pitt Hopkins Syndrome NNZ-2591 in Pitt Hopkins Syndrome

2-Jul-2024 Final Director's Interest Notice - T Scott Final Director's Interest Notice - T Scott

2-Jul-2024 Final Director's Interest Notice - T Scott Final Director's Interest Notice - T Scott

17-Jun-2024 Application for quotation of securities - NEU Application for quotation of securities - NEU

13-Jun-2024 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

29-May-2024 Corporate Presentation, 29 May 2024 Corporate Presentation, 29 May 2024

29-May-2024 Corporate Presentation, 29 May 2024 Corporate Presentation, 29 May 2024

29-May-2024 Corporate Presentation, 29 May 2024 Corporate Presentation, 29 May 2024

28-May-2024 Results of Meeting Results of Meeting

28-May-2024 AGM webcast, 28 May 2024 AGM webcast, 28 May 2024

28-May-2024 AGM webcast, 28 May 2024 AGM webcast, 28 May 2024

28-May-2024 AGM Chair Address & CEO Presentation AGM Chair Address & CEO Presentation

28-May-2024 AGM Chair Address & CEO Presentation AGM Chair Address & CEO Presentation

27-May-2024 Investor webinar - Pitt Hopkins Phase 2 results, 27 May 2024 Investor webinar - Pitt Hopkins Phase 2 results, 27 May 2024

27-May-2024 Investor webinar - Pitt Hopkins Phase 2 results, 27 May 2024 Investor webinar - Pitt Hopkins Phase 2 results, 27 May 2024

27-May-2024 Pitt Hopkins Phase 2 results presentation, 27 May 2024 Pitt Hopkins Phase 2 results presentation, 27 May 2024

27-May-2024 Pitt Hopkins Phase 2 results presentation, 27 May 2024 Pitt Hopkins Phase 2 results presentation, 27 May 2024

27-May-2024 Pitt Hopkins syndrome Phase 2 trial results presentation Pitt Hopkins syndrome Phase 2 trial results presentation

16-May-2024 Neuren CEO to present at BIO & Jefferies conferences in US Neuren CEO to present at BIO & Jefferies conferences in US

16-May-2024 Neuren CEO to present at BIO & Jefferies conferences in US Neuren CEO to present at BIO & Jefferies conferences in US

15-May-2024 Investor presentation, 15 May 2024 Investor presentation, 15 May 2024

15-May-2024 Investor presentation, 15 May 2024 Investor presentation, 15 May 2024

7-May-2024 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

7-May-2024 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

26-Apr-2024 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

26-Apr-2024 Notification of cessation of securities - NEU Notification of cessation of securities - NEU

26-Apr-2024 Virtual AGM online guide Virtual AGM online guide

26-Apr-2024 Virtual AGM online guide Virtual AGM online guide

26-Apr-2024 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

26-Apr-2024 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

23-Apr-2024 Appendix 4G Appendix 4G

23-Apr-2024 Appendix 4G Appendix 4G

23-Apr-2024 2023 Annual Report to shareholders 2023 Annual Report to shareholders

23-Apr-2024 2023 Annual Report to shareholders 2023 Annual Report to shareholders

23-Apr-2024 2023 Annual Report to shareholders 2023 Annual Report to shareholders

8-Apr-2024 Application for quotation of securities - NEU Application for quotation of securities - NEU

8-Apr-2024 Application for quotation of securities - NEU Application for quotation of securities - NEU

12-Mar-2024 Application for quotation of securities - NEU Application for quotation of securities - NEU

12-Mar-2024 Application for quotation of securities - NEU Application for quotation of securities - NEU

1-Mar-2024 Investor webinar, 29 February 2024 Investor webinar, 29 February 2024

1-Mar-2024 Investor webinar, 29 February 2024 Investor webinar, 29 February 2024

29-Feb-2024 2023 Results webinar 2023 Results webinar

29-Feb-2024 2023 Results webinar 2023 Results webinar

29-Feb-2024 Neuren 2023 results investor webinar on 29 February 2024 Neuren 2023 results investor webinar on 29 February 2024

29-Feb-2024 Neuren 2023 results investor webinar on 29 February 2024 Neuren 2023 results investor webinar on 29 February 2024

8-Feb-2024 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

8-Feb-2024 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

1-Feb-2024 Application for quotation of securities - NEU Application for quotation of securities - NEU

1-Feb-2024 Application for quotation of securities - NEU Application for quotation of securities - NEU

19-Dec-2023 Application for quotation of securities - NEU Application for quotation of securities - NEU

18-Dec-2023 Company Overview Company Overview

18-Dec-2023 Investor web conference, 18 December 2023 Investor web conference, 18 December 2023

18-Dec-2023 Investor web conference, 18 December 2023 Investor web conference, 18 December 2023

20-Nov-2023 Comment on media speculation Comment on media speculation

20-Nov-2023 Comment on media speculation Comment on media speculation

13-Nov-2023 Neuren completes Phelan-McDermid syndrome Phase 2 trial Neuren completes Phelan-McDermid syndrome Phase 2 trial

13-Nov-2023 Neuren completes Phelan-McDermid syndrome Phase 2 trial Neuren completes Phelan-McDermid syndrome Phase 2 trial

8-Nov-2023 ASX article, 8 Nov 2023 ASX article, 8 Nov 2023

8-Nov-2023 Investor presentation, 8 November 2023 Investor presentation, 8 November 2023

8-Nov-2023 Investor presentation, 8 November 2023 Investor presentation, 8 November 2023

20-Oct-2023 Neuren receives Australian Growth Company of the Year Award Neuren receives Australian Growth Company of the Year Award

20-Oct-2023 Neuren receives Australian Growth Company of the Year Award Neuren receives Australian Growth Company of the Year Award

14-Sep-2023 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

14-Sep-2023 Change of Director's Interest Notice - J Basile Change of Director's Interest Notice - J Basile

29-Aug-2023 Investor web conference, 28 August 2023 Investor web conference, 28 August 2023

29-Aug-2023 Investor web conference, 28 August 2023 Investor web conference, 28 August 2023

28-Aug-2023 Investor presentation, 28 August 2023 Investor presentation, 28 August 2023

28-Aug-2023 Investor presentation, 28 August 2023 Investor presentation, 28 August 2023

28-Aug-2023 Investor presentation, 28 August 2023 Investor presentation, 28 August 2023

28-Aug-2023 Investor presentation, 28 August 2023 Investor presentation, 28 August 2023

28-Aug-2023 Neuren reports 2023 half-year profit after tax of $48m Neuren reports 2023 half-year profit after tax of $48m

28-Aug-2023 Neuren reports 2023 half-year profit after tax of $48m Neuren reports 2023 half-year profit after tax of $48m

25-Aug-2023 Notification of half-year results & investor web conference Notification of half-year results & investor web conference

25-Aug-2023 Notification of half-year results & investor web conference Notification of half-year results & investor web conference

18-Jul-2023 Investor Welcome Investor Welcome

14-Jul-2023 Investor web conference, 14 July 2023 Investor web conference, 14 July 2023

14-Jul-2023 Investor web conference, 14 July 2023 Investor web conference, 14 July 2023

14-Jul-2023 Investor web conference presentation, 14 July 2023 Investor web conference presentation, 14 July 2023

14-Jun-2023 Change of Director's Interest Notice Change of Director's Interest Notice

5-Jun-2023 Neuren presenting at Jefferies Global Healthcare Conference Neuren presenting at Jefferies Global Healthcare Conference

5-Jun-2023 Neuren presenting at Jefferies Global Healthcare Conference Neuren presenting at Jefferies Global Healthcare Conference

5-Jun-2023 Jefferies Global Healthcare Conference, 8 June 2023 Jefferies Global Healthcare Conference, 8 June 2023

2-Jun-2023 AGM webcast, 30 May 2023 AGM webcast, 30 May 2023

2-Jun-2023 AGM webcast, 30 May 2023 AGM webcast, 30 May 2023

30-May-2023 Results of Meeting Results of Meeting

30-May-2023 Results of Meeting Results of Meeting

30-May-2023 AGM Chair Address & CEO Presentation AGM Chair Address & CEO Presentation

30-May-2023 AGM Chair Address & CEO Presentation AGM Chair Address & CEO Presentation

30-May-2023 AGM Chair Address & CEO Presentation AGM Chair Address & CEO Presentation

26-May-2023 IRSF Physician Panel: Answering Your Questions About Trofinetide IRSF Physician Panel: Answering Your Questions About Trofinetide

26-May-2023 IRSF Physician Panel: Answering Your Questions About Trofinetide IRSF Physician Panel: Answering Your Questions About Trofinetide

15-May-2023 IRSF Parent Panel: My Trofinetide Clinical Trial Experience IRSF Parent Panel: My Trofinetide Clinical Trial Experience

15-May-2023 IRSF Parent Panel: My Trofinetide Clinical Trial Experience IRSF Parent Panel: My Trofinetide Clinical Trial Experience

28-Apr-2023 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

28-Apr-2023 Virtual AGM online guide Virtual AGM online guide

27-Apr-2023 Appendix 4G Appendix 4G

27-Apr-2023 2022 Annual Report to shareholders 2022 Annual Report to shareholders

27-Apr-2023 2022 Annual Report to shareholders 2022 Annual Report to shareholders

27-Apr-2023 2022 Annual Report to shareholders 2022 Annual Report to shareholders

27-Mar-2023 Application for quotation of securities - NEU Application for quotation of securities - NEU

20-Mar-2023 Proactive interview, 20 March 2023 Proactive interview, 20 March 2023

20-Mar-2023 Proactive interview, 20 March 2023 Proactive interview, 20 March 2023

17-Mar-2023 Investor webinar, 14 March 2023 Investor webinar, 14 March 2023

17-Mar-2023 Investor webinar, 14 March 2023 Investor webinar, 14 March 2023

14-Mar-2023 Ausbiz interview, 14 March 2023 Ausbiz interview, 14 March 2023

14-Mar-2023 Investor Presentation, 14 March 2023 Investor Presentation, 14 March 2023

14-Mar-2023 Investor Presentation, 14 March 2023 Investor Presentation, 14 March 2023

14-Mar-2023 Investor Presentation, 14 March 2023 Investor Presentation, 14 March 2023

13-Mar-2023 Notification of investor webinar Notification of investor webinar

13-Mar-2023 Notification of investor webinar Notification of investor webinar

13-Mar-2023 Finance News Network interview, 13 March 2023 Finance News Network interview, 13 March 2023

2-Mar-2023 Initial Director's Interest Notice Initial Director's Interest Notice

2-Mar-2023 Neuren appoints Joe Basile to board of directors Neuren appoints Joe Basile to board of directors

2-Mar-2023 Neuren appoints Joe Basile to board of directors Neuren appoints Joe Basile to board of directors

1-Mar-2023 Investor presentation, 1 March 2023 Investor presentation, 1 March 2023

24-Feb-2023 Investor Presentation, 24 February 2023 Investor Presentation, 24 February 2023

21-Feb-2023 Application for quotation of securities - NEU Application for quotation of securities - NEU

21-Dec-2022 MST Financial Late Stage Biotech Forum MST Financial Late Stage Biotech Forum

19-Dec-2022 Thank You Thank You

19-Dec-2022 Publications Publications

7-Dec-2022 MST Financial: Late Stage Biotech Forum, 30 Nov 2022 MST Financial: Late Stage Biotech Forum, 30 Nov 2022

7-Dec-2022 Becoming a substantial holder Becoming a substantial holder

2-Dec-2022 Ceasing to be a substantial holder Ceasing to be a substantial holder

29-Nov-2022 Bell Potter Healthcare Conference, 8 Nov 2022 Bell Potter Healthcare Conference, 8 Nov 2022

23-Nov-2022 Change in substantial holding Change in substantial holding

17-Nov-2022 Jefferies London Healthcare Conference presentation, 17 Nov 2022 Jefferies London Healthcare Conference presentation, 17 Nov 2022

10-Nov-2022 Neuren on Marcus Today Podcast, 7 Nov 2022 Neuren on Marcus Today Podcast, 7 Nov 2022

27-Oct-2022 Q3 2022 quarterly activity and cash flow report Q3 2022 quarterly activity and cash flow report

20-Oct-2022 Neuren receives US$10 million milestone payment Neuren receives US$10 million milestone payment

14-Oct-2022 Trofinetide in Fragile X Syndrome Trofinetide in Fragile X Syndrome

22-Sep-2022 View Update Report: MST Access 27 September 2022 View Update Report: MST Access 27 September 2022

14-Sep-2022 Investor presentation, 14 September 2022 Investor presentation, 14 September 2022

14-Sep-2022 Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference

13-Sep-2022 Rett Syndrome NDA accepted for Priority Review by FDA Rett Syndrome NDA accepted for Priority Review by FDA

6-Sep-2022 Share Price Information Share Price Information

24-Aug-2022 2021 Annual Report 2021 Annual Report

24-Aug-2022 Half-year shareholder update Half-year shareholder update

24-Aug-2022 Half-year shareholder update Half-year shareholder update

24-Aug-2022 Half Yearly Report and Accounts Half Yearly Report and Accounts

24-Aug-2022 Half Yearly Report and Accounts Half Yearly Report and Accounts

24-Aug-2022 Half Yearly Report and Accounts Half Yearly Report and Accounts

16-Aug-2022 Anti-bribery and Corruption Policy Anti-bribery and Corruption Policy

16-Aug-2022 Whistleblower Policy Whistleblower Policy

16-Aug-2022 Continuous Disclosure Policy Continuous Disclosure Policy

16-Aug-2022 Risk Management Policy Risk Management Policy

16-Aug-2022 Remuneration Committee Charter Remuneration Committee Charter

16-Aug-2022 Audit Committee Charter Audit Committee Charter

16-Aug-2022 Securities Trading Policy Securities Trading Policy

16-Aug-2022 Code of Conduct Code of Conduct

8-Aug-2022 Investor presentation, 8 August 2022 Investor presentation, 8 August 2022

8-Aug-2022 Investor presentation, 8 August 2022 Investor presentation, 8 August 2022

8-Aug-2022 Investor presentation, 8 August 2022 Investor presentation, 8 August 2022

8-Aug-2022 Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS

8-Aug-2022 Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS

29-Jul-2022 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Activities/Appendix 4C Cash Flow Report

29-Jul-2022 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Activities/Appendix 4C Cash Flow Report

27-Jul-2022 View Update Report: MST Access 27 July 2022 View Update Report: MST Access 27 July 2022

27-Jul-2022 MST Access update report 27 July 2022 MST Access update report 27 July 2022

19-Jul-2022 Acadia submits Rett Syndrome New Drug Application to the FDA Acadia submits Rett Syndrome New Drug Application to the FDA

19-Jul-2022 Acadia submits Rett Syndrome New Drug Application to the FDA Acadia submits Rett Syndrome New Drug Application to the FDA

18-Jul-2022 View Update Report: MST Access 18 July 2022 View Update Report: MST Access 18 July 2022

18-Jul-2022 MST Access update report 18 July 2022 MST Access update report 18 July 2022

12-Jul-2022 Neuren commences Phase 2 trial of NNZ-2591 in Angelman Neuren commences Phase 2 trial of NNZ-2591 in Angelman

12-Jul-2022 Neuren commences Phase 2 trial of NNZ-2591 in Angelman Neuren commences Phase 2 trial of NNZ-2591 in Angelman

8-Jul-2022 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

8-Jul-2022 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

8-Jul-2022 Neuren appoints Chief Medical Officer in United States Neuren appoints Chief Medical Officer in United States

8-Jul-2022 Neuren appoints Chief Medical Officer in United States Neuren appoints Chief Medical Officer in United States

24-Jun-2022 AusBiz interview 22 June 2022 AusBiz interview 22 June 2022

22-Jun-2022 AusBiz interview 22 June 2022 AusBiz interview 22 June 2022

30-May-2022 Results of Meeting Results of Meeting

30-May-2022 Results of Meeting Results of Meeting

30-May-2022 AGM Chairman's Address & CEO Presentation AGM Chairman's Address & CEO Presentation

30-May-2022 AGM Chairman's Address & CEO Presentation AGM Chairman's Address & CEO Presentation

30-May-2022 AGM Chairman's Address & CEO Presentation AGM Chairman's Address & CEO Presentation

4-May-2022 Acadia Q1 2022 earnings call transcript Acadia Q1 2022 earnings call transcript

29-Apr-2022 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Activities/Appendix 4C Cash Flow Report

29-Apr-2022 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Activities/Appendix 4C Cash Flow Report

28-Apr-2022 Virtual AGM online guide Virtual AGM online guide

28-Apr-2022 Virtual AGM online guide Virtual AGM online guide

28-Apr-2022 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

28-Apr-2022 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

27-Apr-2022 Change in substantial holding Change in substantial holding

27-Apr-2022 Change in substantial holding Change in substantial holding

27-Apr-2022 Appendix 4G Appendix 4G

27-Apr-2022 Appendix 4G Appendix 4G

27-Apr-2022 Annual Report to shareholders Annual Report to shareholders

27-Apr-2022 Annual Report to shareholders Annual Report to shareholders

27-Apr-2022 Annual Report to shareholders Annual Report to shareholders

4-Apr-2022 Australian Financial Review article 4 Apr 2022 Australian Financial Review article 4 Apr 2022

4-Apr-2022 Australian Financial Review Apr 2022 Australian Financial Review Apr 2022

30-Mar-2022 View Update Report: MST Access 30 March 2022 View Update Report: MST Access 30 March 2022

25-Mar-2022 FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial

25-Mar-2022 FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial

23-Mar-2022 FDA approval for Phelan-McDermid IND and Phase 2 trial FDA approval for Phelan-McDermid IND and Phase 2 trial

23-Mar-2022 FDA approval for Phelan-McDermid IND and Phase 2 trial FDA approval for Phelan-McDermid IND and Phase 2 trial

11-Mar-2022 Ethics approval for Angelman Phase 2 trial in Australia Ethics approval for Angelman Phase 2 trial in Australia

11-Mar-2022 Ethics approval for Angelman Phase 2 trial in Australia Ethics approval for Angelman Phase 2 trial in Australia

25-Feb-2022 Investor webinar, 25 February 2022 Investor webinar, 25 February 2022

25-Feb-2022 Investor presentation 25 Feb 2022 Investor presentation 25 Feb 2022

25-Feb-2022 Investor presentation 25 Feb 2022 Investor presentation 25 Feb 2022

25-Feb-2022 FDA approval for Angelman IND and Phase 2 trial FDA approval for Angelman IND and Phase 2 trial

25-Feb-2022 FDA approval for Angelman IND and Phase 2 trial FDA approval for Angelman IND and Phase 2 trial

25-Feb-2022 Investor webinar, 25 February 2022 Investor webinar, 25 February 2022

24-Feb-2022 2021 Results - a transformational year for Neuren 2021 Results - a transformational year for Neuren

24-Feb-2022 2021 Results - a transformational year for Neuren 2021 Results - a transformational year for Neuren

24-Feb-2022 Preliminary Final Report and 2021 Full Year Accounts Preliminary Final Report and 2021 Full Year Accounts

24-Feb-2022 Preliminary Final Report and 2021 Full Year Accounts Preliminary Final Report and 2021 Full Year Accounts

24-Feb-2022 Preliminary Final Report and 2021 Full Year Accounts Preliminary Final Report and 2021 Full Year Accounts

14-Feb-2022 View Update Report: MST Access 14 February 2022 View Update Report: MST Access 14 February 2022

3-Feb-2022 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

3-Feb-2022 Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

1-Feb-2022 Neuren appoints Vice President, Corporate Development Neuren appoints Vice President, Corporate Development

1-Feb-2022 Neuren appoints Vice President, Corporate Development Neuren appoints Vice President, Corporate Development

31-Jan-2022 Q4 2021 quarterly activity and cash flow report Q4 2021 quarterly activity and cash flow report

31-Jan-2022 Q4 2021 quarterly activity and cash flow report Q4 2021 quarterly activity and cash flow report

10-Dec-2021 Becoming a substantial holder Becoming a substantial holder

10-Dec-2021 AusBiz interview 8 December 2021 AusBiz interview 8 December 2021

7-Dec-2021 Positive topline results from Phase 3 trial in Rett syndrome Positive topline results from Phase 3 trial in Rett syndrome

12-Nov-2021 View Update Report 12 November 2021 View Update Report 12 November 2021

10-Nov-2021 Neuren presenting at Bell Potter Healthcare Conference Neuren presenting at Bell Potter Healthcare Conference

28-Oct-2021 Q3 2021 quarterly activity and cash flow report Q3 2021 quarterly activity and cash flow report

21-Oct-2021 Neuren receives feedback on IND for Phelan-McDermid syndrome Neuren receives feedback on IND for Phelan-McDermid syndrome

20-Oct-2021 Change of Director's Interest Notice - D Angus Change of Director's Interest Notice - D Angus

11-Oct-2021 US patent to 2034 granted for Neuren's NNZ-2591 in autism US patent to 2034 granted for Neuren's NNZ-2591 in autism

8-Oct-2021 Change of Director's Interest Notice - J Harry Change of Director's Interest Notice - J Harry

8-Oct-2021 Change of Director's Interest Notice - J Pilcher Change of Director's Interest Notice - J Pilcher

8-Oct-2021 Change of Director's Interest Notice - P Davies Change of Director's Interest Notice - P Davies

8-Oct-2021 Application for quotation of securities - NEU Application for quotation of securities - NEU

6-Oct-2021 Update - Proposed issue of securities - NEU Update - Proposed issue of securities - NEU

6-Oct-2021 $3.3 million raised from oversubscribed SPP $3.3 million raised from oversubscribed SPP

1-Oct-2021 Feedback on Angelman IND and submission of Pitt Hopkins IND Feedback on Angelman IND and submission of Pitt Hopkins IND

22-Sep-2021 View Extract - Edition 902 22 September 2021 View Extract - Edition 902 22 September 2021

21-Sep-2021 IND application submitted for NNZ-2591 in Phelan-McDermid IND application submitted for NNZ-2591 in Phelan-McDermid

17-Sep-2021 Share Purchase Plan Offer Booklet Share Purchase Plan Offer Booklet

16-Sep-2021 Section 708A Notice Section 708A Notice

16-Sep-2021 New patent issued to 2032 for Neuren's trofinetide in Brazil New patent issued to 2032 for Neuren's trofinetide in Brazil

16-Sep-2021 Application for quotation of securities - NEU Application for quotation of securities - NEU

13-Sep-2021 Investor Presentation, 13 September 2021 Investor Presentation, 13 September 2021

13-Sep-2021 Proposed issue of securities - NEU Proposed issue of securities - NEU

13-Sep-2021 Placement to accelerate NNZ-2591 across 4 indications Placement to accelerate NNZ-2591 across 4 indications

10-Sep-2021 Notification of investor presentation, 9.00 AEST 13 Sept 21 Notification of investor presentation, 9.00 AEST 13 Sept 21

9-Sep-2021 Trading Halt Trading Halt

8-Sep-2021 View Extract - Edition 901 8 September 2021 View Extract - Edition 901 8 September 2021

3-Sep-2021 FDA grants Orphan Drug designation for Prader-Willi syndrome FDA grants Orphan Drug designation for Prader-Willi syndrome

1-Sep-2021 Angelman IND and Ethics applications submitted for NNZ-2591 Angelman IND and Ethics applications submitted for NNZ-2591

1-Sep-2021 Trofinetide Rett syndrome clinical trial in girls aged 2-5 Trofinetide Rett syndrome clinical trial in girls aged 2-5

30-Aug-2021 R&D Tax Incentive Advance Overseas Finding Approval R&D Tax Incentive Advance Overseas Finding Approval

25-Aug-2021 Half-year shareholder update Half-year shareholder update

25-Aug-2021 Half Yearly Report and Accounts Half Yearly Report and Accounts

25-Aug-2021 Half Yearly Report and Accounts Half Yearly Report and Accounts

17-Aug-2021 Notification of investor webinar Notification of investor webinar

11-Aug-2021 View Update Report 11 August 2021 View Update Report 11 August 2021

11-Aug-2021 View Extract - Edition 899 11 August 2021 View Extract - Edition 899 11 August 2021

5-Aug-2021 Phase 3 enrolment successfully completed, results in Q4 2021 Phase 3 enrolment successfully completed, results in Q4 2021

3-Aug-2021 Diggers & Dealers Presentation Diggers & Dealers Presentation

30-Jul-2021 Q2 2021 quarterly activity and cash flow report Q2 2021 quarterly activity and cash flow report

2-Jul-2021 Peak TV interview 2 July 2021 Peak TV interview 2 July 2021

29-Jun-2021 MST Access Australian Micro & Small Caps Conference 2021 15 June 2021 MST Access Australian Micro & Small Caps Conference 2021 15 June 2021

28-Jun-2021 Change of Director's Interest Notice Change of Director's Interest Notice

22-Jun-2021 Results of Meeting Results of Meeting

22-Jun-2021 AGM Chairman's Address and CEO Presentation AGM Chairman's Address and CEO Presentation

16-Jun-2021 Change of Director's Interest Notice Change of Director's Interest Notice

15-Jun-2021 View Extract - Edition 895 15 June 2021 View Extract - Edition 895 15 June 2021

15-Jun-2021 Investor presentation, 15 June 2021 Investor presentation, 15 June 2021

15-Jun-2021 Initial Director's Interest Notice Initial Director's Interest Notice

15-Jun-2021 Neuren CEO Jon Pilcher appointed to board of directors Neuren CEO Jon Pilcher appointed to board of directors

10-Jun-2021 Neuren to present at MST Access investor conference Neuren to present at MST Access investor conference

10-Jun-2021 Update - Annual General Meeting 2021 Update - Annual General Meeting 2021

3-Jun-2021 Phelan McDermid Syndrome Foundation - Interview with Neuren Pharmaceuticals about upcoming Phelan-McDermid clinical trial Phelan McDermid Syndrome Foundation - Interview with Neuren Pharmaceuticals about upcoming Phelan-McDermid clinical trial

1-Jun-2021 Positive FDA meetings enable INDs for three Phase 2 trials Positive FDA meetings enable INDs for three Phase 2 trials

21-May-2021 Virtual AGM online guide Virtual AGM online guide

21-May-2021 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

29-Apr-2021 New patent issued to 2032 for Neuren's trofinetide in Canada New patent issued to 2032 for Neuren's trofinetide in Canada

27-Apr-2021 Appendix 4G Appendix 4G

27-Apr-2021 Annual Report to shareholders Annual Report to shareholders

27-Apr-2021 Annual Report to shareholders Annual Report to shareholders

22-Apr-2021 Quarterly report and cash flow statement for Q1 2021 Quarterly report and cash flow statement for Q1 2021

19-Apr-2021 View Extract - Edition 888 19 April 2021 View Extract - Edition 888 19 April 2021

23-Mar-2021 Investor presentation, 23 March 2021 Investor presentation, 23 March 2021

10-Mar-2021 Neuren successfully completes manufacturing for Phase 2 Neuren successfully completes manufacturing for Phase 2

9-Mar-2021 Euroz Hartleys Rottnest Conference Presentation Euroz Hartleys Rottnest Conference Presentation

24-Feb-2021 Neuren corporate presentation, 24 February 2021 Neuren corporate presentation, 24 February 2021

24-Feb-2021 Neuren approaching transforming milestones in 2021 Neuren approaching transforming milestones in 2021

24-Feb-2021 Preliminary Final Report and 2020 full year accounts Preliminary Final Report and 2020 full year accounts

24-Feb-2021 Preliminary Final Report and 2020 full year accounts Preliminary Final Report and 2020 full year accounts

18-Feb-2021 View Update Report 18 Feb 2021 View Update Report 18 Feb 2021

18-Feb-2021 Change of Director's Interest Notice Change of Director's Interest Notice

17-Feb-2021 Notification of investor briefing webinar Notification of investor briefing webinar

16-Feb-2021 View Update Report 16 Feb 2021 View Update Report 16 Feb 2021

16-Feb-2021 Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline

15-Feb-2021 Successful Phase 1 trial for Neuren's NNZ-2591 Successful Phase 1 trial for Neuren's NNZ-2591

29-Jan-2021 Quarterly report and cash flow statement for Q4 2020 Quarterly report and cash flow statement for Q4 2020

12-Jan-2021 Neuren Pharmaceuticals receives EC Orphan designations for drug candidate NNZ-2591 Neuren Pharmaceuticals receives EC Orphan designations for drug candidate NNZ-2591

11-Jan-2021 European Commission grants 3 NNZ-2591 Orphan designations European Commission grants 3 NNZ-2591 Orphan designations

7-Dec-2020 Notification of investor briefing webinar Notification of investor briefing webinar

7-Dec-2020 Positive opinion for all 3 Orphan applications in Europe Positive opinion for all 3 Orphan applications in Europe

19-Nov-2020 Approval received for final stage of NNZ-2591 clinical trial Approval received for final stage of NNZ-2591 clinical trial

19-Nov-2020 Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial

5-Nov-2020 View Update Report 5 November 2020 View Update Report 5 November 2020

29-Oct-2020 Quarterly report and cash flow statement for Q3 2020 Quarterly report and cash flow statement for Q3 2020

29-Sep-2020 Neuren requests Orphan designations for NNZ-2591 in Europe Neuren requests Orphan designations for NNZ-2591 in Europe

22-Sep-2020 Neuren initiates manufacture of NNZ-2591 for Phase 2 trials Neuren initiates manufacture of NNZ-2591 for Phase 2 trials

27-Aug-2020 Success Success

26-Aug-2020 Half-year Shareholder Update Half-year Shareholder Update

26-Aug-2020 Half Yearly Report and Accounts Half Yearly Report and Accounts

26-Aug-2020 Half Yearly Report and Accounts Half Yearly Report and Accounts

18-Aug-2020 Corporate presentation, 18 August 2020 Corporate presentation, 18 August 2020

11-Aug-2020 Change of Director's Interest Notice Change of Director's Interest Notice

7-Aug-2020 Appendix 2A Appendix 2A

7-Aug-2020 Change of Director's Interest Notice Change of Director's Interest Notice

5-Aug-2020 Completion of Share Purchase Plan Completion of Share Purchase Plan

30-Jul-2020 Appointment of CFO & Company Secretary Appointment of CFO & Company Secretary

27-Jul-2020 Q2 2020 Activity Report and Cash Flow Report Q2 2020 Activity Report and Cash Flow Report

14-Jul-2020 Final share buy-back notice - Appendix 3F Final share buy-back notice - Appendix 3F

14-Jul-2020 Announcement of buy-back - Appendix 3C Announcement of buy-back - Appendix 3C

14-Jul-2020 Publication in Pediatric Neurology: Berry-Kravis E et al., A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome Publication in Pediatric Neurology: Berry-Kravis E et al., A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome

14-Jul-2020 Poster at 72nd Annual Meeting of American Academy of Neurology Poster at 72nd Annual Meeting of American Academy of Neurology

Trofinetide: a novel approach to Rett syndrome. Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Jones NE, Youakim JM.

14-Jul-2020 Publications and presentations for trofinetide and NNZ-2591 Publications and presentations for trofinetide and NNZ-2591

13-Jul-2020 Appendix 3G Appendix 3G

9-Jul-2020 Share Purchase Plan Offer Booklet Share Purchase Plan Offer Booklet

6-Jul-2020 Section 708A notice Section 708A notice

6-Jul-2020 Appendix 2A Appendix 2A

1-Jul-2020 Electing to receive SPP documents by e-mail Electing to receive SPP documents by e-mail

29-Jun-2020 Results of Meeting Results of Meeting

29-Jun-2020 AGM Chairman's Address and CEO Presentation AGM Chairman's Address and CEO Presentation

29-Jun-2020 Proposed issue of Securities - NEU Proposed issue of Securities - NEU

29-Jun-2020 Neuren successfully completes $20m capital raising Neuren successfully completes $20m capital raising

25-Jun-2020 Trading Halt Trading Halt

16-Jun-2020 Temporary enrolment pause ended in Phase 3 trial in the US Temporary enrolment pause ended in Phase 3 trial in the US

2-Jun-2020 Change of Director's Interest Notice Change of Director's Interest Notice

1-Jun-2020 Change of Director's Interest Notice Change of Director's Interest Notice

29-May-2020 Final Director's Interest Notice Final Director's Interest Notice

28-May-2020 View Update Report 28 May 2020 View Update Report 28 May 2020

28-May-2020 Virtual AGM online guide Virtual AGM online guide

28-May-2020 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

27-May-2020 Neuren announces changes to leadership team Neuren announces changes to leadership team

7-May-2020 Neuren commences first clinical trial for NNZ-2591 Neuren commences first clinical trial for NNZ-2591

29-Apr-2020 Appendix 4G Appendix 4G

29-Apr-2020 Annual Report 2019 Annual Report 2019

29-Apr-2020 Annual Report 2019 Annual Report 2019

17-Apr-2020 Appendix 4C - quarterly Appendix 4C - quarterly

17-Apr-2020 Q1 2020 Activity Report Q1 2020 Activity Report

6-Apr-2020 Corporate presentation, 6 April 2020 Corporate presentation, 6 April 2020

2-Apr-2020 First patent in Israel granted for trofinetide First patent in Israel granted for trofinetide

26-Mar-2020 Change of Director's Interest Notice Change of Director's Interest Notice

26-Mar-2020 International institution acquires 14% of Neuren International institution acquires 14% of Neuren

24-Mar-2020 Change of Director's Interest Notice Change of Director's Interest Notice

24-Mar-2020 Temporary pause in new enrolments for LAVENDER trial in US Temporary pause in new enrolments for LAVENDER trial in US

20-Mar-2020 Trading Halt Trading Halt

17-Mar-2020 Neuren to capture substantially greater value after Phase 3 Neuren to capture substantially greater value after Phase 3

10-Mar-2020 Additional information Additional information

6-Mar-2020 Compelling results for 2591 dose ranging study in PMS model Compelling results for 2591 dose ranging study in PMS model

4-Mar-2020 Commentary on potential benefit to Neuren of RPD designation Commentary on potential benefit to Neuren of RPD designation

4-Mar-2020 Rare Pediatric Disease designation received from FDA Rare Pediatric Disease designation received from FDA

4-Mar-2020 Neuren Pharmaceuticals secures Rare Pediatric Disease designation for trofinetide to treat Rett Syndrome Neuren Pharmaceuticals secures Rare Pediatric Disease designation for trofinetide to treat Rett Syndrome

26-Feb-2020 5 Orphan Drug programs and Rett in Phase 3 funded by partner 5 Orphan Drug programs and Rett in Phase 3 funded by partner

26-Feb-2020 Appendix 4E and 2019 full year accounts Appendix 4E and 2019 full year accounts

26-Feb-2020 Appendix 4E and 2019 full year accounts Appendix 4E and 2019 full year accounts

19-Feb-2020 Update on trofinetide Phase 3 trial in Rett syndrome Update on trofinetide Phase 3 trial in Rett syndrome

28-Jan-2020 Appendix 4C - quarterly Appendix 4C - quarterly

12-Dec-2019 2019 year-end update and 2020 outlook 2019 year-end update and 2020 outlook

3-Dec-2019 Patent to 2034 granted in Europe for Neuren's NNZ-2591 Patent to 2034 granted in Europe for Neuren's NNZ-2591

14-Nov-2019 View Initiation Report 14 November 2019 View Initiation Report 14 November 2019

31-Oct-2019 Phase 3 trial of trofinetide in Rett syndrome commences Phase 3 trial of trofinetide in Rett syndrome commences

18-Oct-2019 Neuren Corporate Presentation, October 2019 Neuren Corporate Presentation, October 2019

17-Oct-2019 Appendix 4C - quarterly Appendix 4C - quarterly

16-Oct-2019 FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins

16-Oct-2019 Pause in Trading Pause in Trading

11-Oct-2019 FDA grants Orphan Drug Designation for NNZ-2591 in Angelman FDA grants Orphan Drug Designation for NNZ-2591 in Angelman

20-Sep-2019 Neuren approaching key milestones in Q4 2019 Neuren approaching key milestones in Q4 2019

28-Aug-2019 Neuren advances pipeline for neurodevelopmental disorders Neuren advances pipeline for neurodevelopmental disorders

28-Aug-2019 Half Yearly Report and Accounts Half Yearly Report and Accounts

28-Aug-2019 Half Yearly Report and Accounts Half Yearly Report and Accounts

16-Aug-2019 New patent granted for Neuren's NNZ-2591 in Japan New patent granted for Neuren's NNZ-2591 in Japan

31-Jul-2019 Appendix 4C - quarterly Appendix 4C - quarterly

29-Jul-2019 Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA

16-Jul-2019 Neuren receives final payment from Lanstead Capital Neuren receives final payment from Lanstead Capital

28-May-2019 Results of Meeting Results of Meeting

28-May-2019 Chairman's Address at 2019 Annual Meeting of Shareholders Chairman's Address at 2019 Annual Meeting of Shareholders

28-May-2019 Historical Share Price Calculator Historical Share Price Calculator

27-May-2019 Share Price Calculator Share Price Calculator

17-May-2019 Validation for NNZ-2591 neurodevelopmental disorder pipeline Validation for NNZ-2591 neurodevelopmental disorder pipeline

17-May-2019 NNZ-2591 positive effects in Pitt Hopkins syndrome model NNZ-2591 positive effects in Pitt Hopkins syndrome model

17-May-2019 NNZ-2591 positive effects in Angelman syndrome model NNZ-2591 positive effects in Angelman syndrome model

30-Apr-2019 Appendix 4C - quarterly Appendix 4C - quarterly

29-Apr-2019 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

26-Apr-2019 Appendix 4G Appendix 4G

26-Apr-2019 Annual Report to shareholders Annual Report to shareholders

26-Apr-2019 Annual Report to shareholders Annual Report to shareholders

26-Apr-2019 Update on development plan for NNZ-2591 Update on development plan for NNZ-2591

9-Apr-2019 Top 20 Shareholders Top 20 Shareholders

28-Mar-2019 Neuren's Rett syndrome Phase 2 trial published in Neurology Neuren's Rett syndrome Phase 2 trial published in Neurology

27-Mar-2019 Publication in Neurology®: Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome Publication in Neurology®: Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome

27-Feb-2019 Fundamentals strong as Neuren advances neuroscience pipeline Fundamentals strong as Neuren advances neuroscience pipeline

27-Feb-2019 Preliminary Final Report and statutory accounts Preliminary Final Report and statutory accounts

27-Feb-2019 Preliminary Final Report and statutory accounts Preliminary Final Report and statutory accounts

18-Feb-2019 NNZ-2591 positive effects in Phelan-McDermid syndrome model NNZ-2591 positive effects in Phelan-McDermid syndrome model

4-Feb-2019 Plans for Phase 3 trial in Rett syndrome Plans for Phase 3 trial in Rett syndrome

1-Feb-2019 Neuren retains ex-North America, appoints investment bank Neuren retains ex-North America, appoints investment bank

31-Jan-2019 Appendix 4C - quarterly Appendix 4C - quarterly

3-Jan-2019 Final Director's Interest Notice Final Director's Interest Notice

31-Dec-2018 Ceasing to be a substantial holder Ceasing to be a substantial holder

18-Dec-2018 2018 Year-end Business Update 2018 Year-end Business Update

17-Dec-2018 Larry Glass to retire as a director and continue as CSO Larry Glass to retire as a director and continue as CSO

2-Nov-2018 Presentation at AusBiotech Invest and Partnering 2018 Presentation at AusBiotech Invest and Partnering 2018

31-Oct-2018 Appendix 4C - quarterly Appendix 4C - quarterly

26-Oct-2018 Trofinetide ex-North America exclusive negotiation period Trofinetide ex-North America exclusive negotiation period

17-Oct-2018 Neuren and ACADIA hold Rett syndrome SAB meeting Neuren and ACADIA hold Rett syndrome SAB meeting

1-Oct-2018 Change of Director's Interest Notice Change of Director's Interest Notice

21-Sep-2018 FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID

6-Sep-2018 Investor presentation, 6 September 2018 Investor presentation, 6 September 2018

31-Aug-2018 Half Yearly Report and Accounts Half Yearly Report and Accounts

31-Aug-2018 Half Yearly Report and Accounts Half Yearly Report and Accounts

29-Aug-2018 Neuren and Lanstead agree to pause settlements for 120 days Neuren and Lanstead agree to pause settlements for 120 days

22-Aug-2018 Appointment of auditor Appointment of auditor

22-Aug-2018 Neuren receives initial payment of US$10 million from ACADIA Neuren receives initial payment of US$10 million from ACADIA

16-Aug-2018 Change of Director's Interest Notice Change of Director's Interest Notice

15-Aug-2018 Change of Director's Interest Notice Change of Director's Interest Notice

7-Aug-2018 Investor update Investor update

7-Aug-2018 Neuren and ACADIA announce agreement for North America Neuren and ACADIA announce agreement for North America

31-Jul-2018 Appendix 4C - quarterly Appendix 4C - quarterly

26-Jul-2018 Prospectus Prospectus

9-Jul-2018 Initial Director's Interest Notice Initial Director's Interest Notice

5-Jul-2018 Initial Director's Interest Notice Initial Director's Interest Notice

5-Jul-2018 Initial Director's Interest Notice Initial Director's Interest Notice

4-Jul-2018 Neuren announces new appointments to the board of directors Neuren announces new appointments to the board of directors

18-Jun-2018 Results of Meeting Results of Meeting

18-Jun-2018 Chairman's Address at 2018 Annual Shareholders' Meeting Chairman's Address at 2018 Annual Shareholders' Meeting

30-May-2018 Change of Director's Interest Notice Change of Director's Interest Notice

30-May-2018 Final share buy-back notice - Appendix 3F Final share buy-back notice - Appendix 3F

30-May-2018 Announcement of buy-back - Appendix 3C Announcement of buy-back - Appendix 3C

23-May-2018 Notice under section 708A(5)(e) of the Corporations Act Notice under section 708A(5)(e) of the Corporations Act

23-May-2018 Appendix 3B Appendix 3B

21-May-2018 Neuren announces investment and exclusive negotiation period Neuren announces investment and exclusive negotiation period

14-May-2018 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

8-May-2018 Appendix 4G Appendix 4G

8-May-2018 Annual Report to shareholders Annual Report to shareholders

8-May-2018 Annual Report to shareholders Annual Report to shareholders

30-Apr-2018 Appendix 4C - quarterly Appendix 4C - quarterly

30-Apr-2018 First patent in Japan granted for Neuren's trofinetide First patent in Japan granted for Neuren's trofinetide

29-Mar-2018 Full Year Statutory Accounts Full Year Statutory Accounts

29-Mar-2018 Full Year Statutory Accounts Full Year Statutory Accounts

29-Mar-2018 Disclosure under Listing Rule 4.3D Disclosure under Listing Rule 4.3D

28-Feb-2018 Preliminary Final Report Preliminary Final Report

28-Feb-2018 Preliminary Final Report Preliminary Final Report

30-Jan-2018 Appendix 4C - quarterly Appendix 4C - quarterly

29-Dec-2017 Final Director's Interest Notice Final Director's Interest Notice

29-Dec-2017 Non-executive director retirement Non-executive director retirement

27-Dec-2017 Change in substantial holding Change in substantial holding

5-Dec-2017 Neuren Pharmaceuticals gets green light for a patent in the U.S. Neuren Pharmaceuticals gets green light for a patent in the U.S.

5-Dec-2017 Neuren announces new US patent to be granted for NNZ-2591 Neuren announces new US patent to be granted for NNZ-2591

16-Nov-2017 Consolidation/Split - NEU Consolidation/Split - NEU

16-Nov-2017 Notification under Listing Rule 7.20 of share reorganisation Notification under Listing Rule 7.20 of share reorganisation

26-Oct-2017 Appendix 4C - quarterly Appendix 4C - quarterly

13-Oct-2017 Neuren FDA meeting confirms Phase 3 plan for Rett syndrome Neuren FDA meeting confirms Phase 3 plan for Rett syndrome

6-Oct-2017 Investor presentation, 6 October 2017 Investor presentation, 6 October 2017

5-Oct-2017 Presentations and publication for Rett syndrome trials Presentations and publication for Rett syndrome trials

30-Aug-2017 Change of Director's Interest Notice Change of Director's Interest Notice

30-Aug-2017 Change of Director's Interest Notice Change of Director's Interest Notice

30-Aug-2017 Change of Director's Interest Notice Change of Director's Interest Notice

29-Aug-2017 Notice under section 708A(5)(e) of the Corporations Act Notice under section 708A(5)(e) of the Corporations Act

29-Aug-2017 Appendix 3B Appendix 3B

29-Aug-2017 Results of Meeting Results of Meeting

24-Aug-2017 Neuren reports 2017 half-year results Neuren reports 2017 half-year results

24-Aug-2017 Half Yearly Report and Accounts Half Yearly Report and Accounts

24-Aug-2017 Half Yearly Report and Accounts Half Yearly Report and Accounts

14-Aug-2017 Notice of special meeting of shareholders Notice of special meeting of shareholders

27-Jul-2017 Appendix 4C - quarterly Appendix 4C - quarterly

21-Jul-2017 Becoming a substantial holder Becoming a substantial holder

20-Jul-2017 Neuren granted Type B Meeting with FDA for Rett syndrome Neuren granted Type B Meeting with FDA for Rett syndrome

19-Jul-2017 Notice under section 708A(5)(e) of the Corporations Act Notice under section 708A(5)(e) of the Corporations Act

19-Jul-2017 Appendix 3B Appendix 3B

13-Jul-2017 Notice under section 708A(5)(e) of the Corporations Act Notice under section 708A(5)(e) of the Corporations Act

13-Jul-2017 Appendix 3B Appendix 3B

29-Jun-2017 Results of Meeting Results of Meeting

29-Jun-2017 2017 AGM Chairman's Address 2017 AGM Chairman's Address

29-Jun-2017 Neuren secures funding for key activities for Rett syndrome Neuren secures funding for key activities for Rett syndrome

29-Jun-2017 Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials

28-Jun-2017 Response to ASX Price Query Response to ASX Price Query

27-Jun-2017 Trading Halt Trading Halt

2-Jun-2017 Investor presentation, 2 June 2017 Investor presentation, 2 June 2017

31-May-2017 Neuren announces grant of two new patents to 2032 Neuren announces grant of two new patents to 2032

29-May-2017 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

8-May-2017 Response to Appendix 4C Query Response to Appendix 4C Query

28-Apr-2017 Appendix 4C - quarterly Appendix 4C - quarterly

28-Apr-2017 Appendix 4G Appendix 4G

28-Apr-2017 Annual Report to shareholders Annual Report to shareholders

28-Apr-2017 Annual Report to shareholders Annual Report to shareholders

4-Apr-2017 Neuren receives $1 million R&D Tax Incentive Neuren receives $1 million R&D Tax Incentive

3-Apr-2017 Investor presentation, 3 April 2017 Investor presentation, 3 April 2017

30-Mar-2017 Full Year Statutory Accounts Full Year Statutory Accounts

30-Mar-2017 Full Year Statutory Accounts Full Year Statutory Accounts

22-Mar-2017 Trofinetide significant clinical benefit in Rett syndrome Trofinetide significant clinical benefit in Rett syndrome

22-Mar-2017 Neuren Pharmaceuticals drug shows promise in treating Rett syndrome Neuren Pharmaceuticals drug shows promise in treating Rett syndrome

19-Mar-2017 Neuren Pharmaceuticals granted ASX trading halt pending trial update Neuren Pharmaceuticals granted ASX trading halt pending trial update

17-Mar-2017 Trading Halt Trading Halt

6-Mar-2017 Annual Thumb Annual Thumb

23-Feb-2017 Preliminary Final Report Preliminary Final Report

23-Feb-2017 Preliminary Final Report Preliminary Final Report

2-Feb-2017 Investor presentation, 2 February 2017 Investor presentation, 2 February 2017

31-Jan-2017 Appendix 4C - quarterly Appendix 4C - quarterly

30-Jan-2017 Neuren completes Phase 2 trial in pediatric Rett syndrome Neuren completes Phase 2 trial in pediatric Rett syndrome

6-Dec-2016 Results of Meeting Results of Meeting

25-Nov-2016 Investor presentation, 25 November 2016 Investor presentation, 25 November 2016

14-Nov-2016 Notice of special meeting of shareholders Notice of special meeting of shareholders

14-Nov-2016 Neuren completes enrolment in Rett syndrome Phase 2 trial Neuren completes enrolment in Rett syndrome Phase 2 trial

31-Oct-2016 Appendix 4C - quarterly Appendix 4C - quarterly

28-Oct-2016 Neuren receives $0.9m from exercise of last expiring options Neuren receives $0.9m from exercise of last expiring options

28-Oct-2016 Appendix 3B Appendix 3B

31-Aug-2016 Change of Director's Interest Notice Change of Director's Interest Notice

31-Aug-2016 Appendix 3B Appendix 3B

30-Aug-2016 Half Yearly Report and Accounts Half Yearly Report and Accounts

30-Aug-2016 Half Yearly Report and Accounts Half Yearly Report and Accounts

25-Aug-2016 Neuren expands Phase 2 Rett syndrome pediatric trial Neuren expands Phase 2 Rett syndrome pediatric trial

25-Aug-2016 Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome

26-Jul-2016 Appendix 4C - quarterly Appendix 4C - quarterly

13-Jul-2016 Asx Cashflow March Quarter Asx Cashflow March Quarter

6-Jul-2016 Investor Fact Sheet Investor Fact Sheet

29-Jun-2016 Corporate Directory Corporate Directory

27-Jun-2016 Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome

24-Jun-2016 Neuren presents at Rettsyndrome.org 2016 Research Symposium Neuren presents at Rettsyndrome.org 2016 Research Symposium

23-Jun-2016 Poster at Rettsyndrome.org 2016 Rett Syndrome Symposium Poster at Rettsyndrome.org 2016 Rett Syndrome Symposium

Improving outcome measures for Rett Syndrome (RTT) clinical trials: Development of CSS/MBA change indexes to assess treatment outcome

22-Jun-2016 Grant of new patent for Autism Spectrum Disorders Grant of new patent for Autism Spectrum Disorders

22-Jun-2016 Presentation by Daniel Glaze, MD, at Rettsyndrome.org 2016 Rett Syndrome Symposium Presentation by Daniel Glaze, MD, at Rettsyndrome.org 2016 Rett Syndrome Symposium

Past, Present and Future: A program to develop and establish Trofinetide as a safe and effective treatment for Rett syndrome

31-May-2016 Results of Meeting Results of Meeting

31-May-2016 Chairman's Address to Shareholders Chairman's Address to Shareholders

16-May-2016 Change of Director's Interest Notice Change of Director's Interest Notice

13-May-2016 Presentation at 6th Annual TBI Conference, Washington DC Presentation at 6th Annual TBI Conference, Washington DC

12-May-2016 Presentation at 6th Annual TBI Conference, Washington DC Presentation at 6th Annual TBI Conference, Washington DC

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury

2-May-2016 Notice of Annual General Meeting/Proxy Form Notice of Annual General Meeting/Proxy Form

29-Apr-2016 Appendix 4C - quarterly Appendix 4C - quarterly

26-Apr-2016 Neuren Shareholder Update Neuren Shareholder Update

26-Apr-2016 Results of Phase 2 trial in moderate to severe TBI Results of Phase 2 trial in moderate to severe TBI

22-Apr-2016 Trading Halt Trading Halt

22-Apr-2016 Neuren Pharmaceuticals Ltd to reveal clinical results Neuren Pharmaceuticals Ltd to reveal clinical results

18-Apr-2016 Appendix 4G Appendix 4G

18-Apr-2016 Annual Report to shareholders Annual Report to shareholders

18-Apr-2016 Annual Report to shareholders Annual Report to shareholders

7-Apr-2016 First subject commences Neuren's Rett syndrome Phase 2 trial First subject commences Neuren's Rett syndrome Phase 2 trial

25-Feb-2016 Neuren reports 2015 full-year financial results Neuren reports 2015 full-year financial results

25-Feb-2016 Appendix 4E and Financial Report 31 December 2015 Appendix 4E and Financial Report 31 December 2015

29-Jan-2016 Appendix 4C - quarterly Appendix 4C - quarterly

11-Jan-2016 Neuren Investor Presentation, 11 January 2016 Neuren Investor Presentation, 11 January 2016

4-Jan-2016 Neuren Shareholder Update, January 2016 Neuren Shareholder Update, January 2016

30-Dec-2015 Appendix 3B Appendix 3B

7-Dec-2015 Trofinetide successful in Phase 2 trial in Fragile X Trofinetide successful in Phase 2 trial in Fragile X

3-Dec-2015 Trading Halt Trading Halt

30-Nov-2015 Grant of composition patent in Europe for Neuren's NNZ-2591 Grant of composition patent in Europe for Neuren's NNZ-2591

17-Nov-2015 Corporations Act Notice Corporations Act Notice

17-Nov-2015 Appendix 3B Appendix 3B

9-Nov-2015 Shareholders provide further support for Rett syndrome Shareholders provide further support for Rett syndrome

29-Oct-2015 Neuren completes enrolment in INTREPID clinical trial Neuren completes enrolment in INTREPID clinical trial

21-Oct-2015 Appendix 4C - quarterly Appendix 4C - quarterly

13-Oct-2015 IRSF confirms financial support for Neuren's clinical trials IRSF confirms financial support for Neuren's clinical trials

12-Oct-2015 New US patent covering use of trofinetide for Rett syndrome New US patent covering use of trofinetide for Rett syndrome

29-Sep-2015 Neuren provides update on Fragile X and INTREPID trials Neuren provides update on Fragile X and INTREPID trials

25-Aug-2015 Half Yearly Report and Accounts 30 June 2015 Half Yearly Report and Accounts 30 June 2015

25-Aug-2015 Half Yearly Report and Accounts 30 June 2015 Half Yearly Report and Accounts 30 June 2015

14-Aug-2015 trofinetide confirmed as INN for Neuren's NNZ-2566 trofinetide confirmed as INN for Neuren's NNZ-2566

13-Aug-2015 Neuren confirms orphan drug designations in Europe Neuren confirms orphan drug designations in Europe

31-Jul-2015 Investor presentation, 31 July 2015 Investor presentation, 31 July 2015

30-Jul-2015 Appendix 4C - quarterly Appendix 4C - quarterly

29-Jul-2015 Neuren reports progress in orphan drug programs Neuren reports progress in orphan drug programs

1-Jun-2015 Appendix 3B Appendix 3B

7-May-2015 Appendix 3B Appendix 3B